Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Avecho Biotechnology Limited ( (AU:AVE) ) is now available.
Avecho Biotechnology Limited has announced a significant update on its Phase III clinical trial for its CBD TPM-enhanced capsule aimed at treating insomnia. The company has dosed 131 patients and is on track to complete recruitment of the required 210 patients for interim analysis by the second half of 2025, with results expected in early 2026. This trial, the largest of its kind for cannabidiol, is being conducted across multiple sites in Australia and is designed to meet international regulatory standards. The progress in recruitment, aided by new trial sites and revised criteria, marks a crucial milestone for Avecho, potentially impacting its market positioning and offering new treatment options for insomnia, a condition affecting a significant portion of the global population.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited develops and commercializes innovative human and animal health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM), which enhances the solubility and absorption of drugs and nutrients. Its lead asset is a cannabidiol (CBD) TPM soft-gel capsule designed to increase CBD absorption, currently in Phase III clinical development for insomnia treatment.
Current Market Cap: A$14.28M
See more insights into AVE stock on TipRanks’ Stock Analysis page.